ConductScience.org, home

Paper20007699

BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.

Yuan H and 7 others. J Biol Chem, 2010. Cited by 42 papers, by iCite.

Cite this record

ConductScience Library. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. Papers, record 20007699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20007699

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
PubMed
Journal
J Biol Chem
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
42
iCite
Relative citation ratio, by iCite
0.83
iCite
Revised in PubMed
2021-10-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yuan HHongfeng
2Wang ZZhiqiang
3Gao CChunggang
4Chen WWengang
5Huang QQin
6Yee JKJiing-Kuan
7Bhatia RRavi
8Chen WWenYong

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug Resistance, NeoplasmMajor topic
Fusion Proteins, bcr-ablMajor topic
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMajor topic
Antineoplastic Agents
Apoptosis
Benzamides
Blotting, Western
Cell Cycle
Cell Line
Cell Proliferation
Humans
Imatinib Mesylate
Immunoprecipitation
In Situ Hybridization, Fluorescence
Mutation
Piperazines
Pyrimidines
RNA, Small Interfering
Reactive Oxygen Species

Source PubMed

Download CSV of topics

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16321612Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis.Int J Cell Cloning1983https://conductscience.org/library/papers/6321612PubMed
29345054The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.Blood1997https://conductscience.org/library/papers/9345054PubMed
316527898BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.Blood2006https://conductscience.org/library/papers/16527898PubMed
415459011A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.Blood2005https://conductscience.org/library/papers/15459011PubMed
517303698Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.Blood2007https://conductscience.org/library/papers/17303698PubMed
617470736Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.J Natl Cancer Inst2007https://conductscience.org/library/papers/17470736PubMed
712730117Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.Blood2003https://conductscience.org/library/papers/12730117PubMed
812869662Specific targeted therapy of chronic myelogenous leukemia with imatinib.Pharmacol Rev2003https://conductscience.org/library/papers/12869662PubMed
911780146Structure of the Bcr-Abl oncoprotein oligomerization domain.Nat Struct Biol2002https://conductscience.org/library/papers/11780146PubMed
1017189410Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.Clin Cancer Res2006https://conductscience.org/library/papers/17189410PubMed
1112887890Autoinhibition of Bcr-Abl through its SH3 domain.Mol Cell2003https://conductscience.org/library/papers/12887890PubMed
1215705718Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.Proc Natl Acad Sci U S A2005https://conductscience.org/library/papers/15705718PubMed
138246975A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.Mol Cell Biol1993https://conductscience.org/library/papers/8246975PubMed
1411423618Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.Science2001https://conductscience.org/library/papers/11423618PubMed
1512499247Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).Cancer Res2002https://conductscience.org/library/papers/12499247PubMed
169808572Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.Blood1998https://conductscience.org/library/papers/9808572PubMed
1715289338Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.Cancer Res2004https://conductscience.org/library/papers/15289338PubMed
1815256671Overriding imatinib resistance with a novel ABL kinase inhibitor.Science2004https://conductscience.org/library/papers/15256671PubMed
1914758366Rational siRNA design for RNA interference.Nat Biotechnol2004https://conductscience.org/library/papers/14758366PubMed
2017522713Chronic myeloid leukaemia as a model of disease evolution in human cancer.Nat Rev Cancer2007https://conductscience.org/library/papers/17522713PubMed

See all 43 referencesDownload CSV of references

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.

PMIDTitleJournalYearIn PapersSource
36453102Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition.Haematologica2023https://conductscience.org/library/papers/36453102PubMed
36379918BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia.Cell Death Discov2022https://conductscience.org/library/papers/36379918PubMed
35524023Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.Int J Hematol2022https://conductscience.org/library/papers/35524023PubMed
35338182Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model.Sci Rep2022https://conductscience.org/library/papers/35338182PubMed
34873458Recent advances of SIRT1 and implications in chemotherapeutics resistance in cancer.Am J Cancer Res2021https://conductscience.org/library/papers/34873458PubMed
34659899Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.Am J Cancer Res2021https://conductscience.org/library/papers/34659899PubMed
34616685Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining.Front Oncol2021https://conductscience.org/library/papers/34616685PubMed
33918810GSK-3α Inhibition in Drug-Resistant CML Cells Promotes Susceptibility to NK Cell-Mediated Lysis in an NKG2D- and NKp30-Dependent Manner.Cancers (Basel)2021https://conductscience.org/library/papers/33918810PubMed
33334308Inferring time-dependent population growth rates in cell cultures undergoing adaptation.BMC Bioinformatics2020https://conductscience.org/library/papers/33334308PubMed
32708713PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells.Cancers (Basel)2020https://conductscience.org/library/papers/32708713PubMed
31761618CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.EBioMedicine2019https://conductscience.org/library/papers/31761618PubMed
30787317Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.Sci Rep2019https://conductscience.org/library/papers/30787317PubMed
30711891A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML.Leuk Res2019https://conductscience.org/library/papers/30711891PubMed
30049824BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.Haematologica2018https://conductscience.org/library/papers/30049824PubMed
29967475T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.Sci Rep2018https://conductscience.org/library/papers/29967475PubMed
29608815Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.ChemMedChem2018https://conductscience.org/library/papers/29608815PubMed
29116012Connexin 32 and connexin 43 are involved in lineage restriction of hepatic progenitor cells to hepatocytes.Stem Cell Res Ther2017https://conductscience.org/library/papers/29116012PubMed
28819281Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.Leukemia2017https://conductscience.org/library/papers/28819281PubMed
27726390Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.J Nat Prod2016https://conductscience.org/library/papers/27726390PubMed
27581146A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.Methods Mol Biol2016https://conductscience.org/library/papers/27581146PubMed

See all 35 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABL125PubTator's text mininghttps://conductscience.org/library/genes/25NCBI Gene
BCR613PubTator's text mininghttps://conductscience.org/library/genes/613NCBI Gene
HPRT13251PubTator's text mininghttps://conductscience.org/library/genes/3251NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20007699

GET https://conductscience.org/api/papers/v1/20007699/references?page=2